Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Mar 31, 2021
Revenue for the first quarter ended March 31, 2021 was $0.4 million.
As of March 31, 2021, Adaptimmune had cash and cash equivalents of $32.4 million and Total Liquidity of $317.9 million.
For Fiscal Year Ending Dec 31, 2020
For complete information regarding our financials, see our periodic filings